EphA2-Receptor Targeted PEGylated Nanoliposomes for the Treatment of BRAF<sup>V600E</sup> Mutated Parent- and Vemurafenib-Resistant Melanoma
The clinical outcomes of malignant melanoma have improved with the introduction of mitogen-activated protein kinase kinase (MEK) inhibitors. However, off-target toxicities of the MEK inhibitor trametinib (TMB) often result in dose interruption and discontinuation of therapy. The purpose of this stud...
| Κύριοι συγγραφείς: | , , , , |
|---|---|
| Μορφή: | Άρθρο |
| Γλώσσα: | English |
| Έκδοση: |
MDPI AG
2019-10-01
|
| Σειρά: | Pharmaceutics |
| Θέματα: | |
| Διαθέσιμο Online: | https://www.mdpi.com/1999-4923/11/10/504 |